MRI-Based Radiomics for Preoperative Prediction of Lymphovascular Invasion in Patients With Invasive Breast Cancer

Mayidili Nijiati†, Diliaremu Aihaiti*, Aisikaerjiang Huojia†, Abudukeyoumujiang Abulizi†, Sailidan Mutailifu, Nueramina Rouzi, Guozhao Dai and Patiman Maimaiti

Department of Radiology, The First People’s Hospital of Kashgar, Xinjiang, China

Objective: Preoperative identification of lymphovascular invasion (LVI) in patients with invasive breast cancer is challenging due to absence of reliable biomarkers or tools in clinical settings. We aimed to establish and validate multiparametric magnetic resonance imaging (MRI)-based radiomic models to predict the risk of lymphovascular invasion (LVI) in patients with invasive breast cancer.

Methods: This retrospective study included a total of 175 patients with confirmed invasive breast cancer who had known LVI status and preoperative MRI from two tertiary centers. The patients from center 1 was randomly divided into a training set (n=99) and a validation set (n = 26), while the patients from center 2 was used as a test set (n=50). A total of 1409 radiomic features were extracted from the T2-weighted imaging (T2WI), dynamic contrast-enhanced (DCE) imaging, diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC), respectively. A three-step feature selection including SelectKBest, interclass correlation coefficients (ICC), and least absolute shrinkage and selection operator (LASSO) was performed to identify the features most associated with LVI. Subsequently, a Support Vector Machine (SVM) classifier was trained to develop single-layer radiomic models and fusion radiomic models. Model performance was evaluated and compared by the area under the curve (AUC), sensitivity, and specificity.

Results: Based on one feature of wavelet-HLH_gldm_GrayLevelVariance, the ADC radiomic model achieved an AUC of 0.87 (95% confidence interval [CI]: 0.80–0.94) in the training set, 0.87 (0.70-1.00) in the validation set, and 0.77 (95%CI: 0.64-0.86) in the test set. However, the combination of radiomic features derived from other MR sequences failed to yield incremental value.

Conclusions: ADC-based radiomic model demonstrated a favorable performance in predicting LVI prior to surgery in patients with invasive breast cancer. Such model holds the potential for improving clinical decision-making regarding treatment for breast cancer.

Keywords: breast cancer, lymphovascular invasion, magnetic resonance imaging (MRI), machine learning, radiomics
INTRODUCTION

According to the 2018 global cancer statistics, breast cancer ranks second in the incidence of new cancers (approximately 11.6%) and fifth in cancer-related mortality (approximately 6.6%) (1). Breast cancer has an incidence rate of 24.2% and a mortality rate of 15%, making it the most malignant cancer among women and a veritable “killer of women” (1). The number of new cases of breast cancer has been increasing annually (2). Recent studies have shown that lymphovascular invasion (LVI) by tumors is a crucial prognostic factor affecting patient outcomes and clinical treatment options (3–5). The main causes of death among patients with breast cancer are cancer recurrence and metastasis. Lymphovascular metastasis is the most common form of metastasis in breast cancer and consists in the invasion of regional lymph nodes, allowing cancer cells to reach distant organs (6). In breast cancer, LVI can occur before the appearance of lymph node metastasis and is an indicator of poor prognosis (6). Thus, LVI is considered one of the major criteria for tumor staging, prognostic prediction, and the selection of treatment options (7–9). However, postoperative pathology is currently the only available tool to confirm that tumor vessels promote lymphatic and blood vessel growth and invasion, with no effective method for non-invasively predicting LVI status before surgery.

The emergence of radiomics brings new opportunities in this regard to the field of oncology (10). Radiomics refers to the high-throughput analysis of digitized quantitative and high-dimensional imaging data and integrates histopathology, machine learning, medical statistics, and computer science at multiple levels and from multiple perspectives to yield high-fidelity data for the comprehensive evaluation of various tumor phenotypes (11). Three previous studies applied MRI-based radiomics to predict LVI in patients with breast cancer (12–14); however their results were controversial. Liu et al. built a combined model incorporating dynamic contrast-enhanced (DCE)-based radiomics signature and MRI-reported axillary lymph node (ALN) status with an area under the curve (AUC) of 0.763 (12). Kayadibi et al. identified the apparent diffusion coefficient (ADC)-based radiomic signature as the best model, with an AUC of 0.732 (13). Zhang et al. found that fusion radiomic model of the T2-weighted imaging (T2WI), contrast-enhanced T1-weighted imaging (DCE), and ADC maps achieved better predictive efficacy for LVI status than either of them alone (14). In this current study, we aimed to develop and validate machine learning-based radiomic models using preoperative MRI images as a non-invasive tool for the prediction of LVI status in patients with invasive breast cancer.

MATERIALS AND METHODS

Patient Population

This study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This retrospective cohort study was approved by institutional ethics board and informed consent was waived.

This study included a total of 175 consecutive patients with pathologically confirmed invasive breast cancer who underwent pretherapy contrast-enhanced MRI in two tertiary hospitals between January 2019 and October 2020. All eligible patients met the following inclusion criteria: i) patients with visible primary breast lesions on MRI, ii) patients with newly diagnosed invasive breast cancer by histopathological evaluation of a surgical specimens, and iii) patients underwent mastectomy or lumpectomy within two weeks after MRI scans. The exclusion criteria were as follows: i) patients received biopsy of the breast lesion before MRI scans, ii) patients received neoadjuvant chemotherapy before surgery, and iii) patients with low quality of MR images due to artifacts. The patient inclusion flowchart is shown in Figure 1.

The clinical and radiological information were included as follows: age, tumor location, tumor number, mass shape, tumor diameter, TNM stage, pathological ALN-status, internal enhancement pattern, background parenchymal enhancement, fibroglandular tissue, chest wall invasion, and pectoralis major muscle invasion. The assessment of radiological findings was in accordance with the American College of Radiology Breast Imaging Reporting and Data System (ACR BI-RADS) (15). Histological analysis was performed on specimens obtained at
the surgery. Pathological ALN status was defined as positive if macrometastases or micrometastases were identified in one or more ALNs (12). LVI was assessed on hematoxylin and eosin-stained sections, and was defined as carcinoma cells in a definite endothelial-lined space in the peritumoral breast surrounding the invasive carcinoma (12). The specimens were analyzed by two pathologists with 5 and 16 years of experience in breast cancer who were blinded to the MRI findings.

MRI Examination
All patients underwent conventional MRI, DCE-MRI, and diffusion-weighted imaging (DWI). A Siemens Avanto 1.5T superconducting magnetic resonance scanner, equipped with a 4-channel breast coil and a 6-channel body matrix coil, was used for MRI examination. A GE Signa HDxt 3.0T MR scanner, with an 8-channel phased-array breast coil, was used. Patients were placed in the prone position in the scanner, with both breasts hanging naturally in the coil. Axial and sagittal MR images were obtained from the axilla to the inferior margin of the breast, for MRI examination. A GE Signa HDxt 3.0T MR scanner, with a superconducting magnetic resonance scanner, equipped with a 16-channel breast coil and a 6-channel body matrix coil, was used for MRI examination.

Imaging Preprocessing
Given that the MRI images were acquired from different machines with different parameters, it is needed to eliminate the internal dependence of radiomic features on voxel size. Thus, we used the resampling method with linear interpolation algorithm to normalize the voxel size.

Lesion Delineation and Segmentation
All patients’ T2WI, DCE, DWI, and ADC maps were exported from the picture archiving and communication system into the Radcloud (Huijing Medical Technology Co., Ltd, Beijing, China) software. Subsequently, the region of interest (ROI) was manually and volumetrically segmented by a radiologist with 5 years of experience. All ROIs were then reviewed by a radiologist with 10 years of experience.

ROI delineation rules were as follows: first, on the DCE images, the phase I image with the highest intensity was selected and an ROI was contoured along the margin of the tumor. Second, on the T2WI image, the primary tumor was defined by contouring the margin of the tumor which had a slightly higher signal. Third, the ROI on the DWI images was drawn to cover the entire high-signal-intensity area. Finally, the ROI on DWI images was then transferred to ADC maps. The ROI excluded any visible liquefaction, necrosis, and cystic regions. Figure 2 shows the ROI delineation and pathological image of a case with presence of LVI.

Feature Extraction
A total of 1409 radiomic features were extracted from the DCE, T2WI, DWI, and ADC maps using the PyRadiomics function package (https://pyradiomics.readthedocs.io/). These features were divided into the following three categories: i) First-order statistical features (n=19), such as peak value, mean, variance, quantitatively describe the voxel intensity distribution of the lesion area in MR images through common basic indicators; ii) Shape-based features (n=16), describe the shape and size of the lesion; iii) Texture features (n=72), including Gray Level Co-occurrence Matrix (GLCM, n=24), Gray Level Dependence Matrix (n=16), Gray Level Run Length Matrix (GLRLM, n=16), and Gray Level Size Zone Matrix (GLSZM, n=16); and iv) and (iv) filter-derived features (n=1302): filter ‘wavelet’: n = 744; other filter ‘lbp’, ‘square’, ‘squaredot’, ‘logarithm’, ‘exponential’, ‘gradient’: n = 93 × 6 = 558. The detailed calculation formula for each radiomic feature is provided on the official website (https://pyradiomics.readthedocs.io).

Feature Selection and Radiomic Model Construction
Before the selection of radiomic feature, the normalization processing of all extracted features was performed. To verify the credibility of the manual segmentation between the two radiologists, the MRI scans of 30 patients were randomly selected and segmented by the two radiologists for double-blind interpretation. Interclass correlation coefficients (ICC), which can be used to assess the interobserver reproducibility of ROIs delineated, is obtained from the following equation:

\[ ICC = \frac{(MS_R - MS_E)}{MS_R + \frac{(MS_E - MS)}{n}} \]

MSR: mean square for row; MSC: mean square for columns; MSE: mean square for error; n: number of subjects.

After feature extraction, 80% of the dataset was randomly assigned to training set and for all cases, features were normalized to the normal distribution by mean and variance scaling. The Support Vector Machine (SVM) classifier was used to develop radiomic models based on single sequence and their combinations.

Since some of the extracted features can be invalid for the specific target task, it is necessary to identify features related to a specific task to achieve the optimal predictive performance. First, SelectKBest was applied to select the most significantly relevant feature set with threshold of 0.05. The least absolute shrinkage and selection operator (LASSO) is a regression analysis method that can perform both variable selection and regularization to improve the identification accuracy and interpretability of the
model. For example, it has a tuning parameter to control the penalty of the linear model, which guarantees the minimum penalty when obtaining a model with a smaller number of features, where the penalty is mean square error (MSE). In addition, another parameter controls the correlation of features, making the selected features less relevant. L1 regularization was used as the cost function, the error value of cross validation was 5, and the maximum number of iterations was 1000. The optimization goal of LASSO is:

\[ y = \frac{1}{2 * n_{samples}} ||y - Xw||^2 + \alpha * ||w|| \]

where \( X \) is the radioactivity characteristic matrix, \( y \) is the sample vector marker, \( n \) is the sample number, \( w \) is the coefficient vector regression model, \( \alpha * ||w|| \) is the LASSO punishment. A radiomic score for each patient was then computed using a linear combination of the key features weighted by their LASSO coefficients.

The SVM classifier was built to predict LVI based on final reduced radiomic features. The performance of the models was estimated by the receiver operating characteristic (ROC) curve and confusion matrix analysis with indicators of area under the curve (AUC), accuracy, sensitivity, and specificity.

**Statistical Analysis**

Descriptive statistics and continuous variables were expressed as numbers (percentages) and mean (standard deviation, SD). Statistical analysis was performed using the Python 3.6 (https://www.python.org/). The univariate and multivariate logistic regression analysis was used to identify the independent clinical predictors of LVI status. The packages of...
“pyradiomics” (https://pyradiomics.readthedocs.io/), “scikit-learn” (https://scikit-learn.org/), and “matplotlib” (https://matplotlib.org/) were used for feature selection, model building, and plotting, respectively. A \( P \)-value <0.05 was considered statistically significant.

RESULTS

Patient Characteristics and Clinical Model Construction

Table 1 illustrates the clinical characteristics of patients in all datasets. The proportion of positive LVI was 32% (56/175). The patients from center 1 was randomly divided into a training set (n=99) and a validation set (n = 26), while the patients from center 2 was used as a test set (n=50).

The univariate logistic regression analysis showed that background parenchymal enhancement (\( P = 0.043 \)), chest wall invasion (\( P = 0.022 \)), axillary lymph node metastasis (\( P = 0.014 \)), and pectoralis major muscle invasion (\( P = 0.021 \)) remained as potential predictors of LVI status, however, they were nonsignificant (all \( P \) values >0.05) in the multivariate logistic regression analysis. The clinical model yielded an AUC of 0.74 (95%CI: 0.65–0.82), 0.61 (95%CI: 0.42–0.81), and 0.50 (95%CI: 0.40-0.66) in the training, validation, and test sets, respectively.

Feature Extraction, Selection and Radiomic Signature Construction

Of all the radiomic features extracted, median ICC was 0.887, 871 (62%) features were robust, with ICC > 0.75. After using SelectKbest method and LASSO algorithm, 11, 2, 1, and 1 features were identified to develop the DCE, T2WI, DWI, and ADC based single-layered radiomic models (Table 2). Table 3

| Characteristics | Training dataset (n=99) | Validation dataset (n=26) | Test dataset (n=50) |
|-----------------|-------------------------|---------------------------|--------------------|
| Mean age (years) | 45.8 ± 10.8             | 48.3 ± 9.3                | 53.4 ± 10.7        |
| Tumor location  |                          |                           |                    |
| Left            | 45 (45.5)                | 15 (57.7)                 | 27 (54)            |
| Right           | 54 (54.5)                | 11 (42.3)                 | 23 (46)            |
| Background parenchymal enhancement |           |                           |                    |
| Minimal         | 19 (19.2)                | 7 (26.9)                  | 21 (42)            |
| Mild            | 32 (32.3)                | 8 (30.8)                  | 16 (32)            |
| Moderate        | 43 (43.4)                | 8 (30.8)                  | 13 (26)            |
| Marked          | 5 (5.1)                  | 3 (11.5)                  | 0                  |
| Fibroglandular tissue |                |                           |                    |
| Almost entirely fat | 6 (6.1)               | 3 (11.5)                  | 1 (2)              |
| Scattered fibroglandular tissue | 33 (32.3)         | 11 (42.3)                 | 5 (10)             |
| Heterogeneous fibroglandular tissue | 49 (49.5)     | 9 (34.7)                  | 44 (88)            |
| Extreme fibroglandular tissue | 11 (11.1)        | 3 (11.5)                  | 0                  |
| Chest wall invasion |                    |                           |                    |
| Yes             | 20 (20.2)                | 2 (7.8)                   | 0                  |
| No              | 79 (79.8)                | 24 (92.2)                 | 50 (100)           |
| Pectoralis major muscle invasion |        |                           |                    |
| Yes             | 11 (11.1)                | 2 (7.8)                   | 1 (2)              |
| No              | 88 (88.9)                | 24 (92.2)                 | 49 (98)            |
| Tumor diameter (mm) |                |                           |                    |
| 34.9 ± 19.8     | 30.0 ± 11.4              | 23.7 ± 9.5                |                    |
| Mas shape       |                          |                           |                    |
| Oval            | 2 (2)                    | 0                         | 14 (28)            |
| Round           | 14 (14.1)                | 2 (7.8)                   | 3 (6)              |
| Irregular       | 83 (83.9)                | 24 (92.2)                 | 33 (66)            |
| Internal enhancement pattern |        |                           |                    |
| Homogeneous     | 37 (37.4)                | 7 (26.9)                  | 4 (8)              |
| Heterogeneous   | 50 (50.5)                | 16 (61.5)                 | 44 (88)            |
| Rim enhancement | 7 (7.1)                  | 1 (3.8)                   | 2 (4)              |
| Dark internal septations |     | 5 (5)                     | 2 (7.8)            |
| Tumor number   |                          |                           |                    |
| Solitary        | 71 (71.7)                | 17 (65.4)                 | 39 (78)            |
| ≥2              | 28 (28.3)                | 9 (34.6)                  | 11 (22)            |
| TNM stage       |                          |                           |                    |
| I               | 14 (14.1)                | 3 (11.5)                  | 14 (28)            |
| II              | 51 (51.5)                | 16 (61.5)                 | 28 (56)            |
| III             | 26 (26.3)                | 6 (23.2)                  | 7 (14)             |
| IV              | 8 (8.1)                  | 1 (3.8)                   | 1 (2)              |
| Pathological ALN status |            |                           |                    |
| Absence         | 51 (51.5)                | 16 (61.5)                 | 28 (56)            |
| Single          | 5 (5)                    | 3 (11.5)                  | 6 (10)             |
| ≥2              | 43 (43.5)                | 7 (27)                    | 17 (34)            |
| Models          | Features                                                                 | Number |
|-----------------|---------------------------------------------------------------------------|--------|
| DCE             | original_shape_Maximum2DDiameterColumn                                    | 11     |
|                 | original_glcm_Idmn                                                        |        |
|                 | logarithm_glszm_HighGrayLevelZoneEmphasis                                |        |
|                 | wavelet-LHL_glcm_Idmn                                                    |        |
|                 | wavelet-LHH_glcm_MaximumProbability                                       |        |
|                 | wavelet-LLH_glszm_GrayLevelVariance                                      |        |
|                 | wavelet-LLH_glszm_LowGrayLevelZoneEmphasis                                |        |
|                 | wavelet-LLH_glszm_ZoneEntropy                                            |        |
|                 | wavelet-HHL_glszm_GrayLevelNonUniformityNormalized                       |        |
|                 | wavelet-LHH_glszm_SmallAreaLowGrayLevelEmphasis                          |        |
| T2WI            | wavelet-HHH_glszm_SmallAreaLowGrayLevelEmphasis                           | 2      |
|                 | wavelet-HLH_glr hm_ShortRunEmphasis                                      |        |
| DWI             | wavelet-HHL_glszm_SmallAreaLowGrayLevelEmphasis                          | 1      |
| ADC             | wavelet-HLH_gldm_GrayLevelVariance                                       | 1      |
| DCE+T2WI        | DCE_original_shape_Maximum2DDiameterColumn                                | 12     |
|                 | DCE_exponential_glszm_GrayLevelNonUniformity                              |        |
|                 | DCE_gradient_glszm_ZoneEntropy                                            |        |
|                 | DCE_wavelet-LHH_glc m_JointEnergy                                         |        |
|                 | DCE_wavelet-LLH_glszm_GrayLevelNonUniformityNormalized                    |        |
|                 | T2_wavelet-LHH_glszm_SizeZoneNonUniformityNormalized                     |        |
|                 | T2_wavelet-LLH_glszm_GrayLevelVariance                                   |        |
|                 | T2_wavelet-LLH_glszm_SmallAreaEmphasis                                   |        |
|                 | T2_wavelet-LLH_glr hm_ShortRunHighGrayLevelEmphasis                      |        |
|                 | T2_wavelet-HHH_glszm_GrayLevelEmphasis                                   |        |
|                 | T2_wavelet-HHH_glszm_SmallAreaLowGrayLevelEmphasis                       |        |
|                 | T2_wavelet-LLL_ngtdm_Strength                                            |        |
| DCE+DWI         | DWI_wavelet-HHL_glszm_SmallAreaLowGrayLevelEmphasis                      | 2      |
|                 | DWI_wavelet-HHL_glszm_SmallAreaLowGrayLevelEmphasis                      |        |
| DCE+ADC         | DCE_original_shape_Maximum2DDiameterColumn                                | 7      |
|                 | DCE_wavelet-LLL_gldm_DependenceVariance                                   |        |
|                 | T2_wavelet-HHH_glszm_SmallAreaLowGrayLevelEmphasis                       |        |
|                 | T2_wavelet-LLL_glr hm_ShortRunLowGrayLevelEmphasis                       |        |
| T2WI+DWI        | DWI_wavelet-HHL_glszm_SmallAreaLowGrayLevelEmphasis                      | 8      |
|                 | DWI_wavelet-HHL_glszm_SmallAreaLowGrayLevelEmphasis                      |        |
|                 | T2_wavelet-LHH_glszm_SmallAreaLowGrayLevelEmphasis                       |        |
|                 | T2_wavelet-LHH_glszm_SmallAreaEmphasis                                   |        |
|                 | T2_wavelet-LLL_glr hm_ShortRunLowGrayLevelEmphasis                       |        |
|                 | T2_wavelet-HHH_glszm_SmallAreaLowGrayLevelEmphasis                       |        |
| T2WI+ADC        | T2_wavelet-LHH_glszm_SmallAreaHighGrayLevelEmphasis                      | 3      |
|                 | T2_wavelet-LLL_glszm_SmallAreaEmphasis                                   |        |
|                 | ADC_wavelet-HHH_glr hm_ShortRunEmphasis                                   |        |
| DWI+ADC         | ADC_wavelet-LLL_glr hm_ShortRunEmphasis                                   | 1      |
| DCE+T2WI+DWI    | DCE_wavelet-HHH_glszm_ZoneEntropy                                         | 3      |
|                 | DWI_wavelet-HHL_glszm_SmallAreaLowGrayLevelEmphasis                      |        |
|                 | T2_wavelet-LLL_glszm_SmallAreaEmphasis                                   |        |
| DCE+T2WI+ADC    | T2_wavelet-LHL_firstorder_Skewness                                       | 12     |
|                 | T2_wavelet-LLL_glszm_SmallAreaEmphasis                                   |        |
|                 | T2_wavelet-HHH_glr hm_SmallAreaLowGrayLevelEmphasis                      |        |
|                 | T2_wavelet-HHH_glszm_HighGrayLevelZoneEmphasis                           |        |
|                 | T2_wavelet-HHH_glszm_HighGrayLevelZoneEmphasis                           |        |
|                 | ADC_exponential_gldm_DependenceEntropy                                   |        |
|                 | ADC_wavelet-LHL_firstorder_Maximum                                       |        |
|                 | ADC_wavelet-LHL_firstorder_RootMeanSquared                               |        |
|                 | ADC_wavelet-LHL_firstorder_RootMeanSquared                               |        |

(Continued)
shows the predictive performance of single-layered radiomic models and the fusion radiomic models. The results showed that ADC-based radiomic model achieved the optimal performance, with an AUC of 0.87 (95% CI: 0.80-0.94) in the training set and 0.87 (95% CI: 0.70-1.00) in the validation set. When validated in the test set, the ADC-based yielded an AUC of 0.77 (95% CI: 0.64-0.86).

### DISCUSSION

Breast cancer with LVI is the pathological manifestation of tumor emboli in the lymphatic and blood vessels in the vicinity of invasive breast cancer. The presence of LVI increases the risk of axillary lymph node metastasis and distant metastasis and is associated with a poor prognosis (5). Currently, LVI can only be confirmed via the pathological assessment of specimens after resection. The building of radiomic model allows preoperative evaluation of LVI status. It is of great clinical significance as the presence or absence of LVI is a crucial criterion for treatment planning.

MRI has been used as one of the preferred imaging methods for early screening of breast cancer, assessment of malignancy, and determination of efficacy and prognosis. Previous studies suggested that some MRI features were significantly associated with LVI status, such as background parenchymal enhancement, peritumoral edema, adjacent vessel sign, enhancement types, and MRI-reported axillary lymph node metastasis (14, 16–18). However, these features were somewhat subjective and could be affected by sample size of a study. In this current study, we observed no any clinical variables included were independent risk factors of LVI, possibly due to small sample size of our training set. More objective and reliable markers are desirable to identification of LVI status in patients with breast cancer.

Radiomics uses high-throughput extraction of high-level quantitative features to describe tumor phenotypes objectively and quantitatively. These features are extracted from medical

| Models | Features | Number |
|--------|----------|--------|
| DCE+DWI+ADC | ADC_wavelet-LLH_grlm_ShortRunEmphasis | 1 |
| T2WI+DWI+ADC | ADC_wavelet-LLH_grlm_ShortRunEmphasis | 1 |
| DCE+T2WI+DWI+ADC | ADC_wavelet-LLH_grlm_ShortRunEmphasis | 1 |

| Models | Sensitivity | Specificity | AUC (95% CI) |
|--------|-------------|-------------|--------------|
| ADC | 0.83 | 0.13 | 0.87 (0.80-0.94) |
| DWI | 0.77 | 0.25 | 0.88 (0.59-0.76) |
| T2WI | 0.67 | 0.25 | 0.89 (0.82-0.95) |
| DCE | 0.88 | 0.55 | 0.89 (0.69-0.69) |
| DCE+T2WI | 0.93 | 0.74 | 0.91 (0.84-0.95) |
| DCE+DWI | 0.83 | 0.61 | 0.76 (0.66-0.85) |
| DCE+ADC | 0.71 | 0.60 | 0.71 (0.55) |
| T2WI+DWI | 1.00 | 0.60 | 0.85 (0.78-0.90) |
| T2WI+ADC | 0.83 | 0.60 | 0.71 (0.71-0.71) |
| DWI+ADC | 0.60 | 0.60 | 0.55 (0.99) |
| DCE+T2WI+DWI | 0.93 | 0.67 | 0.91 (0.66-0.67) |
| DCE+T2WI+ADC | 0.90 | 0.67 | 0.93 (0.89-0.97) |
| DCE+DWI+ADC | 0.68 | 0.67 | 0.78 (0.70-0.86) |
| T2WI+DWI+ADC | 0.60 | 0.67 | 0.66 (0.57-0.75) |
| DCE+T2WI+DWI+ADC | 0.68 | 0.68 | 0.78 (0.70-0.86) |
imaging data using advanced mathematical algorithms, revealing tumor features that may not be discernible with the naked eye (19). Radiomics may have great potential in capturing important phenotypic data on tumors, such as intratumoral heterogeneity (20, 21), thus providing valuable information for individualized clinical treatment. The use of radiomic approach to determine the prognostic factors of breast cancer is almost completely dominated by DCE-MRI, which provides not only abundant radiomic data but also functional information reflecting the DCE parameter characteristics of the tumor. Kinetic enhancement curve was identified as a predictor of LVI (22). Liu et al. showed that DCE-based radiomics signature in combination with MRI ALN status was effective in predicting the LVI status, with an AUC of 0.763 (12); however, this study was limited due to lack of external validation and comparison with other MRI sequences. T2WI allows clear delineation of the lesions, high contrast of the surrounding soft tissue, clear depiction of the size and shape of the lesion, and greater sensitivity to cystic changes and necrosis within the lesion. Adding radiomic features extracted from T2WI images may improve the diagnostic performance of other MRI sequences (14). DWI is a functional imaging method that reflects the Brownian motion of water molecules in the body. ADC value is a quantitative indicator associated with the diffusion of water molecules and microcirculatory perfusion. Previous studies have demonstrated that tumor and peritumoral ADC values were significantly correlated with LVI status (23, 24). The quantitative ADC obtained from DWI has been increasingly used to improve the diagnostic accuracy of contrast-enhanced MRI in breast cancer (14). The results of this present study were consistent with a recent study by Kayadibi et al. (13), in which the ADC-based radiomic model could predict LVI status with satisfying performance. Zhang et al. (14) found that the fusion radiomic signature of the T2WI, cT1WI, and ADC maps achieved a better predictive efficacy for LVI than either of them alone, which was inconsistent with our study that reported the combination of multiparametric MRI-derived radiomic features failed to achieve a complementary effect in the prediction of LVI status. Thus, the role of fusion radiomic model needs to be tested in larger datasets.

The limitations of our study need to be acknowledged. First, this was a retrospective study with small sample size, a multicenter study with a larger sample size is warranted. Second, LVI status was only classified as positive or negative in this study. Uematsu et al. (25), divided into four grades according to the number of lymphovascular structures invaded. Further studies should evaluate the association between radiomic features with different grades of LVI. Third, the influence of MRI parameters on the radiomic features was not analyzed due to the small sample size. Finally, only radiomic features derived from the first postcontrast images of DCE-MRI were analyzed due to its crucial role in the diagnostic performance of breast MRI. The precontrast, other DCE-MRI series deserve to be investigated in further studies.

CONCLUSION

Our results showed that radiomic features based on ADC map could be used to effectively predict LVI status in invasive breast cancer, potentially improving preoperative diagnosis and patient-specific treatment planning. However, the findings of this preliminary study need to be validated in larger datasets.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The First People’s Hospital of Kashgar. The ethics committee waived the requirement of written informed consent for participation.

AUTHOR CONTRIBUTIONS

MN, DA, and GD: conception and design. AH: provision of study materials or patients. AA, SM, PM, and NR: collection and assembly of data. MN, AH, and AA: data analysis and interpretation. All authors: manuscript writing and final approval of the manuscript.

FUNDING

This work was supported by the Special Scientific Research Project of Health Young Medical Science and Technology Talents in Xinjiang Uygur Autonomous Region (Grant No. WJWY202103).

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68:394–424.

2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2016. Cancer J Clin (2016) 66:7–30.

3. Huang KT, Kim YA, Kim J, Chu AJ, Chang JH, Oh SW, et al. The Influences of Peritumoral Lymphatic Invasion and Vascular Invasion on the Survival and Recurrence According to the Molecular Subtypes of Breast Cancer. Breast Cancer Res Treat (2017) 163:71–82.
4. Yi M, Mittenend EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, et al. Novel Staging System for Predicting Disease-Specific Survival in Patients With Breast Cancer Treated With Surgery as the First Intervention: Time to Modify the Current American Joint Committee on Cancer Staging System. *J Clin Oncol* (2011) 29:4654–61.

5. Ejlertsen B, Jensen MB, Rank F, Rasmussen BB, Christiansen P, Kroman N, et al. Population-Based Study of Peritumoral Lymphovascular Invasion and Outcome Among Patients With Operable Breast Cancer. *J Natl Cancer Inst* (2009) 101:729–35.

6. Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, et al. Prognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast Cancer. *Ann Surg* (2004) 240:306–12.

7. Viale G, Giobbie-Hurder A, Gusterson BA, Maiorano E, Mastropasqua MG, Sonzogni A, et al. Adverse Prognostic Value of Peritumoral Vascular Invasion: Is it Abrogated by Adequate Endocrine Adjuvant Therapy? Results From Two International Breast Cancer Study Group Randomized Trials of Chemodendocrine Adjuvant Therapy for Early Breast Cancer. *Ann Oncol* (2010) 21:245–54.

8. Davis BW, Gelber R, Goldhirsh A, Hartmann WH, Hollaway L, Russell I, et al. Prognostic Significance of Peritumoral Vessel Invasion in Clinical Trials of Adjuvant Therapy for Breast Cancer With Axillary Lymph Node Metastasis. *Hum Pathol* (1985) 16:1212–8.

9. Colleoni M, Rotmensz N, Maisonneuve P, Sonzogni A, Pruneri G, Casadio C, et al. Prognostic Role of the Extent of Peritumoral Vascular Invasion in Operable Breast Cancer. *Ann Oncol* (2007) 18:1632–40.

10. Bera K, Braman N, Gupta A, Velcheti V, Madabhushi A. Predicting Cancer Outcomes With Radiomics and Artificial Intelligence in Radiology. *Nat Rev Clin Oncol* (2022) 19:132–46.

11. Lambin P, Leijenaar RTH, Deist TM, Peerlings J, et al. Radiomics: The Bridge Between Medical Imaging and Personalized Medicine. *Nat Rev Clin Oncol* (2017) 14:749–62.

12. Liu Z, Feng B, Li C, Chen Y, Chen Q, Li X, et al. Preoperative Prediction of Lymphovascular Invasion in Invasive Breast Cancer With Dynamic Contrast-Enhanced MRI-Based Radiomics. *J Magn Reson Imaging* (2019) 50:847–57.

13. Kayadbı Y, Kocak B, Ucar N, Akan YN, Yıldırım E, Bektas S. MRI Radiomics of Breast Cancer: Machine Learning-Based Prediction of Lymphovascular Invasion Status. *Acad Radiol* (2022) null:S126–34.

14. Zhang J, Wang G, Ren J, Yang Z, Li D, Cui Y, et al. Multiparametric MRI-Based Radiomics Nomogram for Preoperative Prediction of Lymphovascular Invasion and Clinical Outcomes in Patients With Breast Invasive Ductal Carcinoma. *Eur Radiol* (2022) 36(6):4079–89. doi: 10.1007/s00330-021-08504-6

15. Magno SJ, Shikhman R, Keppke AL. Breast Imaging Reporting and Datasystem, ACR BI-RADS. In: *American College of Radiology, 4th ed*. Reston, VA: StatPearls Publishing, Treasure Island (FL) (2003).

16. Ni-Jia-Ti MY, Ai-Hai-Ti DL, Huo-Jia AS, Wu-Mai-Er PL, A-Bu-Li-Zi AB, Shi Y, et al. Development of a Risk-Stratification Scoring System for Predicting Lymphovascular Invasion in Breast Cancer. *BMC Cancer* (2020) 20:94.

17. Li J, Mo Y, He B, Gao Q, Luo C, Peng C, et al. Association Between MRI Background Parenchymal Enhancement and Lymphovascular Invasion and Estrogen Receptor Status in Invasive Breast Cancer. *Br J Radiol* (2019) 92:20190417.

18. Koh J, Park AY, Ko KH, Jung HK. Can Enhancement Types on Preoperative MRI Reflect Prognostic Factors and Surgical Outcomes in Invasive Breast Cancer? *Eur Radiol* (2019) 29:7000–8.

19. Cheon H, Kim HJ, Lee SM, Cho SH, Shin KM, Kim GC, et al. Preoperative MRI Features Associated With Lymphovascular Invasion in Node-Negative Invasive Breast Cancer: A Propensity-Matched Analysis. *J Magn Reson Imaging* (2017) 46:1037–44.

20. Lim Y, Ko ES, Han BK, Ko EY, Choi JS, Lee JE, et al. Background Parenchymal Enhancement on Breast MRI: Association With Recurrence-Free Survival in Patients With Newly Diagnosed Invasive Breast Cancer. *Breast Cancer Res Treat* (2017) 163:573–86.

21. Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images Are More Than Pictures, They Are Data. *Radiology* (2016) 278:563–77.

22. Grossmann P, Stringfield O, El-Hachem N, Bui MM, Rios Velazquez E, Parmar C, et al. Defining the Biological Basis of Radiomic Phenotypes in Lung Cancer. *Elife* (2017) 6:e23421.

23. Guo Y, Hu Y, Qiao M, Wang Y, Yu J, Li J, et al. Radiomics Analysis on Ultrasound for Prediction of Biologic Behavior in Breast Invasive Ductal Carcinoma. *Clin Breast Cancer* (2018) 18:e335–44.

24. Choi BB. Dynamic Contrast Enhanced-MRI and Diffusion-Weighted Image as Predictors of Lymphovascular Invasion in Node-Negative Invasive Breast Cancer. *World J Surg Oncol* (2021) 19:76.

25. Mori N, Mugikura S, Takasawa C, Miyashita M, Shimauchi A, Ota H, et al. Peritumoral Apparent Diffusion Coefficients for Prediction of Lymphovascular Invasion in Clinically Node-Negative Invasive Breast Cancer. *Eur Radiol* (2016) 26:331–9.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.